A Bioequivalence Study of Amlitelimab Delivered by 2 Different Devices in Healthy Adult Participants
Completed · Phase 1 · NCT07146750
Conditions: Healthy Volunteers
At a glance
- Research payments reported, 2025
- $2.5M
- U.S. investigators named
- 1
- Sites paid
- 1
- Planned or actual enrollment
- 212
About the trial
- Sponsor
- Sanofi
- Tested
- SAR445229 (combination_product)
- Dates
- Started 2025-08-25; completion 2026-04-08
- Results posted
- Not yet
This is a single-center, open-label, randomized, single-dose, parallel, Phase 1, 4-arm study designed to determine the bioequivalence and investigate the safety and tolerability profiles of subcutaneous amlitelimab delivered by 2 different devices at 2 different total doses in healthy adult participants.
From ClinicalTrials.gov, last updated 2026-04-20. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Sanofi US Services Inc. reported $2.5M in research payments for this study in 2025 (12 payments).
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Erg Holding Company Llc $2.5M
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.